JP7257377B2 - Ｃｎｇｂ１連鎖性網膜色素変性症の治療のための遺伝子療法 - Google Patents

Ｃｎｇｂ１連鎖性網膜色素変性症の治療のための遺伝子療法 Download PDF

Info

Publication number
JP7257377B2
JP7257377B2 JP2020501858A JP2020501858A JP7257377B2 JP 7257377 B2 JP7257377 B2 JP 7257377B2 JP 2020501858 A JP2020501858 A JP 2020501858A JP 2020501858 A JP2020501858 A JP 2020501858A JP 7257377 B2 JP7257377 B2 JP 7257377B2
Authority
JP
Japan
Prior art keywords
seq
polynucleotide
sequence identity
nucleic acid
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020501858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511167A (ja
JP2020511167A5 (enExample
Inventor
ミヒャラキス，スティリアノス
ビール，マルティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2020511167A publication Critical patent/JP2020511167A/ja
Publication of JP2020511167A5 publication Critical patent/JP2020511167A5/ja
Application granted granted Critical
Publication of JP7257377B2 publication Critical patent/JP7257377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020501858A 2017-03-21 2018-03-21 Ｃｎｇｂ１連鎖性網膜色素変性症の治療のための遺伝子療法 Active JP7257377B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474409P 2017-03-21 2017-03-21
US62/474,409 2017-03-21
PCT/IB2018/051905 WO2018172961A1 (en) 2017-03-21 2018-03-21 Gene therapy for the treatment of cngb1-linked retinitis pigmentosa

Publications (3)

Publication Number Publication Date
JP2020511167A JP2020511167A (ja) 2020-04-16
JP2020511167A5 JP2020511167A5 (enExample) 2021-04-22
JP7257377B2 true JP7257377B2 (ja) 2023-04-13

Family

ID=62044771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020501858A Active JP7257377B2 (ja) 2017-03-21 2018-03-21 Ｃｎｇｂ１連鎖性網膜色素変性症の治療のための遺伝子療法

Country Status (10)

Country Link
US (2) US12246072B2 (enExample)
EP (1) EP3600446A1 (enExample)
JP (1) JP7257377B2 (enExample)
CN (1) CN111050805B (enExample)
AR (1) AR111188A1 (enExample)
AU (1) AU2018238422B2 (enExample)
CA (1) CA3056211A1 (enExample)
TW (1) TW201902911A (enExample)
UY (1) UY37636A (enExample)
WO (1) WO2018172961A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3116606A1 (en) * 2018-10-15 2020-04-23 Fondazione Telethon Intein proteins and uses thereof
US12605466B2 (en) * 2019-03-04 2026-04-21 University Of Florida Research Foundation, Incorporated Enhanced human opsin promoter for rod specific expression
WO2020182722A1 (en) * 2019-03-08 2020-09-17 Universite Paris-Saclay Improved therapeutic method for rare ocular diseases by gene replacement
CN110241202A (zh) * 2019-06-25 2019-09-17 复旦大学附属眼耳鼻喉科医院 视网膜色素变性突变位点及其应用
WO2021055760A1 (en) 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
WO2021146625A1 (en) * 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
WO2021188761A1 (en) * 2020-03-18 2021-09-23 University Of Florida Research Foundation, Incorporated Modified arrestin-1 to enhance photoreceptor survival in retinal disease
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
JP2023548746A (ja) * 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
CN117480256A (zh) * 2021-03-19 2024-01-30 星际治疗有限公司 治疗剂的眼递送
CN113201556B (zh) * 2021-05-14 2022-11-22 浙江大学 pSOY19-ZM2载体、其制备方法及应用
WO2023280388A1 (en) * 2021-07-06 2023-01-12 Institute Of Molecular And Clinical Ophthalmology Basel Promoter for specific expression of genes in rod photoreceptors
CN115820653A (zh) * 2021-09-17 2023-03-21 深圳华大生命科学研究院 基因突变体及其应用
WO2026087373A1 (en) * 2024-10-21 2026-04-30 MeiraGTx Ocular UK Limited Promoters for driving gene expression in rod photoreceptors and uses thereof
CN119432856B (zh) * 2024-12-30 2025-08-12 云舟生物科技(广州)股份有限公司 核酸分子、病毒颗粒及其制备方法和应用
CN122303228A (zh) * 2024-12-30 2026-06-30 广州市未来基因递送研究院 启动子及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190841A1 (en) 2007-04-12 2010-07-29 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe Genetic suppression and replacement
JP2016530253A (ja) 2013-08-05 2016-09-29 アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3628334T (pt) * 2014-03-21 2023-09-26 Genzyme Corp Terapia genética para retinopatia pigmentar
EP3210632B1 (en) * 2016-02-23 2022-09-28 EyeServ GmbH Gene therapy for the treatment of a retinal degeneration disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190841A1 (en) 2007-04-12 2010-07-29 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe Genetic suppression and replacement
JP2016530253A (ja) 2013-08-05 2016-09-29 アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BATNI, S. et al.，Characterization of the Xenopus Rhodopsin Gene，The Journal of Biological Chemistry，1996年，271(6)，p3179-3186
KOCH, S. et al.，Gene therapy restores vision and delays degeneration in the CNGB1-/- mouse model of retinitis pigmentosa，Human Molecular Genetics，2012年，21(20)，p4486-4496

Also Published As

Publication number Publication date
US20250262328A1 (en) 2025-08-21
WO2018172961A1 (en) 2018-09-27
CA3056211A1 (en) 2018-09-27
UY37636A (es) 2018-10-31
JP2020511167A (ja) 2020-04-16
US12246072B2 (en) 2025-03-11
EP3600446A1 (en) 2020-02-05
AU2018238422A1 (en) 2019-10-03
AU2018238422B2 (en) 2025-04-03
TW201902911A (zh) 2019-01-16
AR111188A1 (es) 2019-06-12
US20200030458A1 (en) 2020-01-30
CN111050805A (zh) 2020-04-21
CN111050805B (zh) 2026-04-14

Similar Documents

Publication Publication Date Title
US20250262328A1 (en) Gene Therapy for the Treatment of CNGB1-linked Retinitis Pigmentosa
JP7452953B2 (ja) １色覚および他の疾患の治療のためのプロモーター、発現カセット、ベクター、キット、ならびに方法
AU2025271096A1 (en) A modified mGluR6 promoter and methods of use
AU2017202320B2 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
JP7692369B2 (ja) シャルコー・マリー・トゥース病のようなシュワン細胞関連疾患を治療するためのミエリンタンパク質ゼロのプロモーターを含むａａｖベクター及びその使用
RS56246B1 (sr) Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu
KR20230043794A (ko) 변이체 캡시드를 갖는 아데노-연관 바이러스 비리온 및 이의 사용 방법
JP2011516049A (ja) 遺伝子障害を治療する方法
JP7397532B2 (ja) 眼遺伝子送達のためのｏｎ双極細胞に特異的なプロモーター
US20220372100A1 (en) KCNV2 Variants and Their Use
EP4534097A1 (en) Composition for treating retinal or macular diseases
KR102704771B1 (ko) 망막 또는 황반 질환 치료용 조성물
HK40121156A (en) Composition for treating retinal or macular diseases
BR122025008690A2 (pt) Polinucleotídeo, vetor, célula in vitro, método para produzir uma partícula de virus recombinante, partícula de virus recombinante e uso
BR112022024345B1 (pt) Polinucleotídeo isolado, vetor, célula procariótica in vitro, método para produzir uma partícula de virus recombinante, partícula de virus recombinante adenoassociado e uso
EA050104B1 (ru) Варианты kcnv2 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230403

R150 Certificate of patent or registration of utility model

Ref document number: 7257377

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250